medigraphic.com
ISSN 1561-3046 (Electronic)

2022, Number 1

<< Back Next >>

Rev Cub Med Mil 2022; 51 (1)

Implications of smoking in the context of COVID-19

Piñera-Castro HJ, Ruiz-González LA

Language: Spanish
References: 26
Page:
PDF size: 263.23 Kb.


ABSTRACT

Introduction: With the spread of the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), questions about the risk factors that influence the coronavirus disease 2019 (COVID-19) have emerged. A widely debated issue has been the potential effect of smoking on SARS-CoV-2 infection rates and the clinical consequences of COVID-19.
Objective: To elucidate the implications of smoking in the context of COVID-19.
Development: In the literature consulted, several pathophysiological mechanisms that support the deleterious effect of smoking in the context of COVID-19 were identified: upregulation of angiotensin-converting enzyme 2; increased expression/activity of transmembrane serine protease 2, cathepsin B/L and furin; immunoinflammation and immunosuppression; upregulation of phosphodiesterase 4; encephalic hemovascular alterations; and morphofunctional modifications of the lung parenchyma.
Conclusions: Smoking has a deleterious effect on patients bearing COVID-19. In this harmful association, there are pathophysiological mechanisms that may make smokers -active or passive ones- more vulnerable to SARS-CoV-2 infection or more likely to present with an unfavorable evolution once they have developed COVID-19.


REFERENCES

  1. Chatkin JM, Godoy I. Are smoking, environmental pollution, and weather conditions risk factors for COVID-19? J Bras Pneumo. 2020 [acceso: 15/04/2021];46(5): e20200183. Disponible en: Disponible en: https://dx.doi.org/10.36416/1806-3756/e20200183

  2. Piñera-Castro HJ. COVID-19 and Guillain-Barré Syndrome: A fortuitous relationship? Rev Mex Neuroci. 2020 [acceso: 15/04/2021];21(5):205-14. Disponible en: Disponible en: https://doi.org/10.24875/RMN.20000079

  3. Grundy EJ, Suddek T, Filippidis FT, Majeed A, Coronini-Cronberg S. Smoking, SARS-CoV-2 and COVID-19: A review of reviews considering implications for public health policy and practice. Tob Induc Dis. 2020 [acceso: 15/04/2021];18(julio):58. Disponible en: Disponible en: https://doi.org/10.18332/tid/124788

  4. Vardavas CI, Nikitara K. COVID-19 and smoking: A systematic review of the evidence. Tob Induc Dis. 2020 [acceso: 15/04/2021];18:20. Disponible en: Disponible en: https://doi.org/10.18332/tid/119324

  5. Kaur G, Lungarella G, Rahman I. SARS-CoV-2 COVID-19 susceptibility and lung inflammatory storm by smoking and vaping. Journal of Inflammation. 2020 [acceso: 15/04/2021];17:21. Disponible en: Disponible en: https://journal-inflammation.biomedcentral.com/track/pdf/10.1186/s12950-020-00250-8.pdf

  6. Reddy RK, Charles WN, Sklavounos A, Dutt A, Seed PT, Khajuria A. The effect of smoking on COVID‐19 severity: A systematic review and meta‐analysis. J Med Virol. 2021 [acceso: 15/04/2021];93(2):1045-1056. Disponible en: Disponible en: https://doi.org/10.1002/jmv.26389

  7. WHO. WHO statement: Tobacco use and COVID-19. 11 Mayo 2020. [acceso: 15/04/2021]. Disponible en: Disponible en: https://www.who.int/news-room/detail/11-05-2020-who-statementtobacco-use-and-covid-19

  8. Aymerich M, Sánchez E. Del conocimiento científico de la investigación clínica a la cabecera del enfermo: las guías de práctica clínica e implementación. Gac Sanit. 2004 [acceso: 15/04/2021];18(4):326-334. Disponible en: Disponible en: https://scielosp.org/article/gs/2004.v18n4/326-334/#

  9. Pranata R, Soeroto AY, Huang I, Lim MA, Santoso P, Permana H, Lukito AA. Effect of chronic obstructive pulmonary disease and smoking on the outcome of COVID-19. Int J Tuberc Lung Dis. 2020 [acceso: 16/04/2021];24(8):838-843. Disponible en: Disponible en: https://doi.org/10.5588/ijtld.20.0278

  10. Chakladar J, Shende N, Li WT, Rajasekaran M, Chang EY, Ongkeko WM. Smoking-Mediated Upregulation of the Androgen Pathway Leads to Increased SARS-CoV-2 Susceptibility. Int J Mol Sci. 2020 [acceso: 16/04/2021];21(10):3627. Disponible en: Disponible en: https://doi.org/10.3390/ijms21103627

  11. Hopkinson NS, Rossi N, El-Sayed_Moustafa J, Laverty AA, Quint JK, Freidin M, et al. Current smoking and COVID-19 risk: results from a population symptom app in over 2.4 million people. Thorax. 2021 [acceso: 16/04/2021];76(7):714-22. Disponible en: Disponible en: https://doi.org/10.1136/thoraxjnl-2020-215119

  12. Li J, Long X, Zhang Q, Fang X, Li N, Fedorova B, Hu S, Li Jh, Xiong N, Lin Z. Tobacco smoking confers risk for severe COVID-19 unexplainable by pulmonary imaging. J Intern Med. 2021 [acceso: 16/04/2021];289(4):574-83. Disponible en: Disponible en: https://doi.org/10.1111/joim.13190

  13. Farsalinos K, Barbouni A, Poulas K, Polosa R, Caponnetto P, Niaura R. Current smoking, former smoking, and adverse outcome among hospitalized COVID-19 patients: a systematic review and meta-analysis. Ther Adv Chronic Dis. 2020 [acceso: 16/04/2021];11:1-14. Disponible en: Disponible en: https://doi.org/10.1177/2040622320935765

  14. Alqahtani JS, Oyelade T, Aldhahir AM, Alghamdi SM, Almehmadi M, Alqahtani AS, et al. Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis. PLoS ONE. 2020 [acceso: 16/04/2021];15(5):e0233147. Disponible en: Disponible en: https://doi.org/10.1371/journal.pone.0233147

  15. Umnuaypornlert A, Kanchanasurakit S, Lucero-Prisno DE, Saokaew S. Smoking and risk of negative outcomes among COVID-19 patients: A systematic review and meta-analysis. Tob Induc Dis. 2021 [acceso: 16/04/2021];19:09. Disponible en: Disponible en: https://doi.org/10.18332/tid/132411

  16. Jiménez-Ruiz CA, López-Padilla D, Alonso-Arroyo A, Aleixandre-Benavent R, Solano-Reina S, Granda-Orivee JI. COVID-19 y tabaquismo: revisión sistemática y metaanálisis de la evidencia. Arch Bronconeumol. 2020 [acceso: 17/04/2021]; 57(S1):21-34. Disponible en: Disponible en: https://doi.org/10.1016/j.arbres.2020.06.024

  17. Smith JC, Sausville EL, Girish V, Yuan ML, Vasudevan A, John KM, et al. Cigarette Smoke Exposure and Inflammatory Signaling Increase the Expression of the SARS-CoV-2 Receptor ACE2 in the Respiratory Tract. Developmental Cell. 2020 [acceso: 17/04/2021];53(5):514-29. Disponible en: Disponible en: https://doi.org/10.1016/j.devcel.2020.05.012

  18. Engin AB, Engin ED, Engin A. Two important controversial risk factors in SARS-CoV-2 infection: Obesity and smoking. Environmental Toxicology and Pharmacology. 2020 [acceso: 17/04/2021];78:103411. Disponible en: Disponible en: https://doi.org/10.1016/j.etap.2020.103411

  19. Oliveira-da Silva AL, Costa Moreira K, Regina Martins S. COVID-19 and smoking: a high-risk association. Cad Saúde Pública. 2020 [acceso: 17/04/2021];36(5):e00072020. Disponible en: Disponible en: https://doi.org/10.1590/0102-311x00072020

  20. Sharif-Askari NS, Sharif-Askari FS, Alabed M, Temsah M, Heialy SA, Hamid Q, Halwani R. Airways Expression of SARS-CoV-2 Receptor, ACE2, and TMPRSS2 Is Lower in Children Than Adults and Increases with Smoking and COPD. Molecular Therapy: Methods & Clinical Development. 2020 [acceso: 18/04/2021];18:1-6. Disponible en: Disponible en: https://doi.org/10.1016/j.omtm.2020.05.013

  21. Lee AC, Chakladar J, Li WT, Chen C, Chang EY, Wang-Rodriguez J, Ongkeko WM. Tobacco, but Not Nicotine and Flavor-Less Electronic Cigarettes, Induces ACE2 and Immune Dysregulation. Int J Mol Sci. 2020 [acceso: 18/04/2021];21(15):5513. Disponible en: Disponible en: https://doi.org/10.3390/ijms21155513

  22. Olds JL, Kabbani N. Is nicotine exposure linked to cardiopulmonary vulnerability to COVID-19 in the general population? The FEBS Journal. 2020 [acceso: 18/04/2021];287(17):3651-5. Disponible en: Disponible en: https://doi.org/10.1111/febs.15303

  23. Archie SR, Cucullo L. Cerebrovascular and Neurological Dysfunction under the Threat of COVID-19: Is There a Comorbid Role for Smoking and Vaping? Int J Mol Sci. 2020 [acceso: 19/04/2021];21:3916. Disponible en: Disponible en: https://doi.org/10.3390/ijms21113916

  24. Lugnier C, Al-Kuraishy HM, Rousseau E. PDE4 inhibition as a therapeutic strategy for improvement of pulmonary dysfunctions in Covid-19 and cigarette smoking. Biochemical Pharmacology. 2021 [acceso: 19/04/2021];185:114431. Disponible en: Disponible en: https://doi.org/10.1016/j.bcp.2021.114431

  25. Zhao Q, Meng M, Kumar R, Wu Y, Huang J, Lian N, et al. The impact of COPD and smoking history on the severity of COVID‐19: A systemic review and meta‐analysis. J Med Virol. 2020 [acceso: 18/04/2021];92(10):1915-21. Disponible en: Disponible en: https://doi.org/10.1002/jmv.25889

  26. Cattaruzza MS, Zagà V, Gallus S, D’Argenio P, Gorini G. Tobacco smoking and COVID-19 pandemic: old and new issues. A summary of the evidence from the scientific literature. Acta Biomed. 2020 [acceso: 19/04/2021];91(2):106-112. Disponible en: Disponible en: https://doi.org/10.23750/abm.v91i2.9698




2020     |     www.medigraphic.com